Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
Evgeny Nasonov,T.V. Korotaeva +1 more
TLDR
The current achievements, trends and recommendations regarding the use of JAK inhibitors in the treatment of IMIDs and also in the hyper-response phase of COVID-19 are reviewed.Abstract:
Despite great advances in the diagnosis and treatment of Immune-mediated inflammatory diseases (IMIDs), which have led to a significant improvement in the prognosis in many patients, the central medical problems of this pathology – restoring the quality of life and reducing mortality to the population level – are far from being resolved. This served as a powerful stimulus for the study of new approaches to the pharmacotherapy of IMIDs, one of which is associated with the discovery of targets for small-molecule therapeutics that inhibit intracellular “signaling” molecules JAKs (Janus kinases). The current achievements, trends and recommendations regarding the use of JAK inhibitors in the treatment of IMIDs and also in the hyper-response phase of COVID-19 are reviewed.read more
Citations
More filters
Journal ArticleDOI
The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
TL;DR: In this article , the authors examined new data on efficacy and safety of OKZ in RA and the prospects of its use in rheumatology ǫ using a clinical trial.
Journal ArticleDOI
Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab
TL;DR: Olokizumab as discussed by the authors , a humanized monoclonal antibody against IL-6, provides a new mode of action by direct inhibition of interleukin (IL) 6.
Journal ArticleDOI
Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022
V. N. Amirjanova,S. Makarov,A. E. Karateev,Alexandr Egorovich Khramov,Sergey Maglevaniy,Alex Rozov,Vadim A. Nesterenko,E. Nasonov +7 more
TL;DR: In this article , the authors present updated guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons on the perioperative treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis and systemic lupus erythematosus undergoing elective total hip or total knee arthroplasty.
АЦЦП-негативный ревматоидный артрит — клинические и иммунологические особенности
TL;DR: In this paper , early diagnosis, regular monitoring of the disease activity and the "treat to target" strategy are recommended for both positive and negative ACCP RA, however, the effectiveness of individual drugs in these subtypes may vary significantly.
Journal ArticleDOI
Molecular mechanisms of the development of the phenomena of peripheral and central sensitization in rheumatoid arthritis
TL;DR: In this paper , the authors considered the molecular biological aspects of the formation of peripheral and central sensitization in RA, with a separate analysis of the pathogenetic role of individual interleukins.
References
More filters
Journal ArticleDOI
Characteristics of SARS-CoV-2 and COVID-19
TL;DR: The basic virology of SARS-CoV-2 is described, including genomic characteristics and receptor use, highlighting its key difference from previously known coronaviruses.
Journal ArticleDOI
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S Smolen,Daniel Aletaha,J. Bijlsma,Ferdinand C. Breedveld,Dimitrios T. Boumpas,Gerd R Burmester,Bernard Combe,Maurizio Cutolo,Maarten de Wit,Maxime Dougados,Paul Emery,A. Gibofsky,Juan J. Gomez-Reino,Boulos Haraoui,Joachim Kalden,Edward C. Keystone,Tore K Kvien,Iain B. McInnes,Emilio Martín-Mola,Carlomaurizio Montecucco,Monika Schoels,Désirée van der Heijde +21 more
TL;DR: The 10 recommendations are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA based on evidence and expert opinion.
Journal ArticleDOI
Cytokine Storm.
David C. Fajgenbaum,Carl H. June +1 more
TL;DR: From the Department of Medicine, Division of Translational Medicine and Human Genetics, Center for Cytokine Storm Treatment and Laboratory, and the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia.
Journal ArticleDOI
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Andre C. Kalil,Thomas F. Patterson,Aneesh K. Mehta,Kay M. Tomashek,Cameron R. Wolfe,Varduhi Ghazaryan,Vincent C. Marconi,Guillermo M. Ruiz-Palacios,Lanny Hsieh,Susan Kline,Victor F. Tapson,Nicole M. Iovine,Mamta K. Jain,Daniel A. Sweeney,Hana M. El Sahly,Angela Branche,Justino Regalado Pineda,David C. Lye,Uriel Sandkovsky,Anne F Luetkemeyer,Stuart H. Cohen,Robert W. Finberg,Patrick E. H. Jackson,Babafemi Taiwo,Catharine I. Paules,Henry Arguinchona,Nathaniel B. Erdmann,Neera Ahuja,Maria G. Frank,Myoung Don Oh,Eu-Suk Kim,Seow Y Tan,Richard A. Mularski,Henrik Nielsen,Philip O Ponce,Barbara S. Taylor,LuAnn Larson,Nadine Rouphael,Youssef Saklawi,Valeria D Cantos,Emily R Ko,John J. Engemann,Alpesh Amin,Miki Watanabe,Joanne Billings,Marie-Carmelle Elie,Richard T. Davey,Timothy Burgess,Jennifer Ferreira,Michelle Green,Mat Makowski,Anabela Cardoso,Stephanie de Bono,Tyler Bonnett,Michael A. Proschan,Gregory A. Deye,Walla Dempsey,Seema U Nayak,Lori E. Dodd,John H. Beigel +59 more
TL;DR: Baricitinib plus remdesivir was superior to remdes Vivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.
Journal ArticleDOI
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Peter D. Richardson,Ivan Griffin,Catherine Tucker,Daniel J. Smith,Olly Oechsle,Anne Phelan,Michael J. Rawling,Edward Savory,Justin Stebbing +8 more
TL;DR: It is suggested that baricitinib could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.
Related Papers (5)
Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis.
Karina Bonfiglioli,Licia Maria Henrique Mota,Ana Cristina de Medeiros Ribeiro,Adriana Maria Kakehasi,Ieda Maria Magalhães Laurindo,Rina Dalva Neubarth Giorgi,Angela Luzia Branco Pinto Duarte,Ana Paula Monteiro Gomides Reis,Mariana Peixoto Guimarães Ubirajara e Silva de Souza,Claiton Viegas Brenol,Geraldo da Rocha Castelar Pinheiro,Cleandro Pires de Albuquerque,Charlles Heldan de Moura Castro,Gustavo Luiz Behrens Pinto,José Fernando Verztman,Luciana Feitosa Muniz,Manoel Barros Bertolo,Maria Raquel da Costa Pinto,Paulo Louzada Júnior,Vitor Alves Cruz,Ivanio Alves Pereira,Max Vitor Carioca Freitas,Bóris Afonso Cruz,Eduardo Paiva,Odirlei André Monticielo,José Roberto Provenza,Ricardo Machado Xavier +26 more